Geburtshilfe Frauenheilkd 2014; 74(3): 233-241
DOI: 10.1055/s-0033-1360170
Guideline
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Vaccination against HPV-Associated Neoplasias

Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society – AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018Impfprävention HPV-assoziierter NeoplasienEmpfehlungen aus der aktuellen S3-Leitlinie des HPV-Management Forums der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. – AWMF Leitlinien-Register Nr. 082-002 (Kurzfassung), gültig bis 31.12.2018
G. Gross
1   Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin, Universität Rostock, Rostock
,
N. Becker
2   Deutsches Krebsforschungszentrum (DKFZ), Epidemiologie von Krebserkrankungen (C020), Heidelberg
,
N. H. Brockmeyer
3   Klinik für Dermatologie und Allergologie der Ruhr-Universität, Bochum
,
S. Esser
4   Klinik für Dermatologie und Venerologie, Universitätsklinikum Essen, Essen
,
U. Freitag
5   Frauenarztpraxis, Wismar
,
M. Gebhardt
6   Frauenselbsthilfe nach Krebs, Forchheim
,
L. Gissmann
7   Deutsches Krebsforschungszentrum (DKFZ), FS Infektion und Krebs, Heidelberg
,
P. Hillemanns
8   Medizinische Hochschule Hannover (MHH), Frauenklinik, Abt. I für Frauenheilkunde und Geburtshilfe, Hannover
,
H. Grundhewer
9   Ausschuss Prävention des Berufsverbandes der Kinder- und Jugendärzte (BVKJ), Berlin
,
H. Ikenberg
10   MVZ für Zytologie und Molekularbiologie (CytoMol), Frankfurt/M.
,
H. Jessen
11   Praxis Jessen + Kollegen, Berlin
,
A. Kaufmann
12   Gynäkologische Tumorimmunologie, Gynäkologie mit Hochschulambulanz, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
,
S. Klug
13   Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
,
J. P. Klußmann
14   Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Klinikum der Universität Gießen, Gießen
,
A. Nast
15   Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
,
D. Pathirana
15   Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
,
K. U. Petry
16   Klinikum Wolfsburg, Abteilung Gynäkologische Onkologie, Wolfsburg
,
H. Pfister
17   Institut für Virologie der Universität zu Köln
,
U. Röllinghof
18   VulvaKarzinom-SHG e. V., Wilhelmshaven
,
P. Schneede
19   Klinikum Memmingen, Klinik für Urologie, Memmingen
,
A. Schneider
20   Klinik und Poliklinik für Gynäkologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
,
E. Selka
18   VulvaKarzinom-SHG e. V., Wilhelmshaven
,
S. Singer
21   Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Institut für Medizinische Biometrie, Epidemiologie und Informatik, Abt. Epidemiologie und Versorgungsforschung, Mainz
,
S. Smola
22   Institut für Virologie, Institut für Infektionsmedizin, Universität des Saarlandes, Homburg/Saar
,
B. Sporbeck
15   Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Allergologie und Venerologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Berlin
,
M. von Knebel Doeberitz
23   Abteilung für Molekulare Pathologie, Pathologisches Institut des Universitätsklinikum Heidelberg, Heidelberg
,
P. Wutzler
24   Universitätsklinikum Jena (Friedrich-Schiller-Universität), Institut für Virologie und Antivirale Therapie, Beutenberg Campus, Jena
› Author Affiliations
Further Information

Publication History

Publication Date:
09 April 2014 (online)

Also available at
   Permissions and Reprints

1 Introduction

Neoplasias associated with anogenital human papilloma viruses (HPV) are characterised by high patient morbidity and mortality and by appreciable limitations in the patientʼs quality of life. Each year 530,000 women worldwide and 4800 women in Germany develop cervical cancer [1], [2]. Biomolecular and epidemiological studies carried out in the past 25 years have demonstrated causal link between persisting infections with HPV 16 and HPV 18 and at least 11 other so-called high-risk HPVs (HR-HPVs) and the development of cervical cancer and its precursor lesions (so-called dysplasias or, respectively, cervical intraepithelial neoplasias – CIN). HPV 16, HPV 18 and other HR-HPVs are also the causes of other cancers and their precursors, for example, vulvar, vaginal, penile and anal cancers as well as tonsillar and throat cancers and certain forms of skin cancer. So-called low-risk HPVs (LR-HPVs) such as HPV 6 and HPV 11 are responsible for over 90 % of anogenital condylomata acuminata (anogenital warts). Condylomata acuminata are the most common viral sexually transmitted disease (STD) worldwide [3]. It is estimated that around 1 % of European and German populations (aged 15–49 years) have these benign but often very unpleasant tumours. The development of a prophylactic quadrivalent vaccine (HPV 6, 11, 16, 18) and a bivalent vaccine (HPV 16, 18) has made it possible to prevent infections of the cervical epithelium and other squamous epithelia and the development of precancerous lesions. In the case of the quadrivalent vaccine (HPV 6, 11, 16, 18), the development of condylomata acuminata can also be prevented. The Standing Committee on Immunisation of the Robert Koch Institute (STIKO) has published a recommendation on HPV vaccination. Based on data from studies on the efficacy of HPV vaccines for the prevention of precancerous lesions of the cervix, vagina, and vulva, the STIKO recommends immunisation for girls aged between 12 and 17 years. The current guidelines do not contradict this recommendation but rather provide a more comprehensive supplement. The S3 guidelines focus on prophylactic vaccination against HPV-16 and HPV-18 or, respectively, HPV-6 and HPV-11 infections and thus on the prevention of cervical, vulvar, vaginal, anal and penile cancer and their precursors as well as on the primary prevention of condylomata acuminata and laryngeal papillomas. This S3 guideline thus clearly differs from other guidelines such as the S1 guideline “Condylomata acuminata and other HPV-associated clinical entities of the genitals, anus and urethra” (Guideline of the German STI Society in cooperation with the German Dermatological Society and the Paul-Ehrlich Society) and the S2 guideline of the German Society for Gynaecology and Obstetrics “Prevention, diagnostics and therapy for HPV infections and HPV-associated pre-invasive lesions in gynaecology and obstetrics”. After the debate on HPV immunisation has been concluded, the S3 guideline for the prevention of cervical cancer issued by the German Society for Gynaecology and Obstetrics will follow the recommendations in the current guideline, which will be updated. The development process and most important contents of the guideline are briefly described below. The long version of the guideline gives a more detailed account (www.awmf.org).

Supporting Information

 

  • References

  • 1 Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N et al. European guidelines for quality assurance in cervical cancer screening. 2nd revised ed. Bertrams; 2008. ISBN: 978-92-79-07698-5
    Google Scholar
  • 2 Jahn I, Eberle A, Niehues C, Birn A, Horch K. Gesundheitsberichterstattung des Bundes, Gebärmuttererkrankungen. Heft 37. Robert Koch-Institut; 2007
    Google Scholar
  • 3 Gross G, Tyring SK eds. Sexually transmitted Infections and sexually transmitted Diseases. Springer; 2011. ISBN: 9783642146626
    CrossrefGoogle Scholar
  • 4 Pathirana D, Hillemanns P, Petry KU, Becker N, Brockmeyer NH, Erdmann R et al. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine 2009; 27: 4551-4559
    CrossrefPubMedGoogle Scholar
  • 5 Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204
    CrossrefPubMedGoogle Scholar
  • 6 Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol 2009; 10: 321-322
    CrossrefPubMedGoogle Scholar
  • 7 Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011; 121: 4593-4599
    CrossrefPubMedGoogle Scholar
  • 8 Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907
    CrossrefPubMedGoogle Scholar
  • 9 Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung. Epidemiologisches Bulletin 2007; 12
    PubMedGoogle Scholar
  • 10 Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765
    Google Scholar
  • 11 Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278
    Google Scholar
  • 12 Esposito S, Birlutiu V, Jarcuska P, Perino A, Man SC, Vladareanu R et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Ped Inf Dis J 2011; 30: e49-e55
    CrossrefPubMedGoogle Scholar
  • 13 Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, Tang Y et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011; 305: 1424-1431
    CrossrefPubMedGoogle Scholar
  • 14 Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. Journal of Womenʼs Health (Larchmont) 2010; 19: 1441-1447
    PubMedGoogle Scholar
  • 15 Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. Br Med J 2012; 344: e1401
    CrossrefPubMedGoogle Scholar
  • 16 Garland S. on behalf of the HPV PATRICIA Study Group. Does the HPV-16/18 AS04-adjuvanted vaccine benefit women with cervical disease? EUROGIN 2011; 2011: May 8 – 11, 2011; Lissabon.
    PubMedGoogle Scholar
  • 17 European Medicines Agency. Cervarix. 2012. Online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124&murl=menus/medicines/medicines.jsp
    PubMedGoogle Scholar
  • 18 Naud P, Roteli-Martins CM, De Carvalho N, Teixeira J, Borba P, Sanchez N et al. HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. Berlin: 27th International papillomavirus conference and clinical workshop. 2011. Online: http://www.hpv2011.org/pics/1/4/Abstract%20Book%202%20APSC%20WEBB%20110922.pdf
    PubMedGoogle Scholar
  • 19 GlaxoSmithKline. Fachinformation Cervarix. 2007. Online: http://www.fachinfo.de/data/fi/jsearch?praep
    PubMedGoogle Scholar
  • 20 Sanofi Pasteur MSD. Fachinformation Gardasil. 2007. Online: http://www.fachinfo.de/data/fi/jsearch?praep
    PubMedGoogle Scholar
  • 21 FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927
    CrossrefPubMedGoogle Scholar
  • 22 Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19: 1783-1793
    CrossrefPubMedGoogle Scholar
  • 23 Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255
    Google Scholar
  • 24 Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Human Vaccines 2007; 3: 109-115
    CrossrefPubMedGoogle Scholar
  • 25 Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170
    Google Scholar
  • 26 De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 1626-1636
    CrossrefPubMedGoogle Scholar
  • 27 Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transplant International: Official Journal of the European Society for Organ Transplantation 2004; 17: 366-369
    PubMedGoogle Scholar
  • 28 Wieland U, Stuecker M, Kreuter A. HPV vaccine against anal intraepithelial neoplasia. N Engl J Med 2012; 366: 378 author reply 378–379
    CrossrefPubMedGoogle Scholar
  • 29 Busnach G, Piselli P, Arbustini E, Baccarani U, Burra P, Carrieri MP et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transpl Proc 2006; 38: 3533-3535
    CrossrefPubMedGoogle Scholar
  • 30 Giuliano AR, Palefsky JM, Goldstone S, Moreira jr. ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364: 401-411
    CrossrefPubMedGoogle Scholar
  • 31 Palefsky JM, Giuliano AR, Goldstone S, Moreira jr. ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-1585
    CrossrefPubMedGoogle Scholar
  • 32 Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC et al. Seroprevalence of human papillomavirus-16, − 18, − 31, and − 45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003; 89: 1248-1254
    CrossrefPubMedGoogle Scholar
  • 33 Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011; 120: 430-438
    CrossrefPubMedGoogle Scholar
  • 34 Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007; 13: 2599-2605
    CrossrefPubMedGoogle Scholar
  • 35 Quigley NB, Potter NT, Chivukula M, Knight MZ, Welch JR, Olson MC. Rate of detection of high-risk HPV with two assays in women >/= 30 years of age. J Clin Virol 2011; 52: 23-27
    CrossrefPubMedGoogle Scholar
  • 36 Bohmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 2003; 189: 118-120
    CrossrefPubMedGoogle Scholar
  • 37 Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1-6
    CrossrefPubMedGoogle Scholar
  • 38 Ikenberg H. Detection of HPV DNA and RNA. In: Pfister H, ed. Monographs in Virology: Prophylaxis and early Detection of HPV-related Neoplasia. Basel: Karger; 2011: 109-119
    Google Scholar
  • 39 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG);, Arbeitsgemeinschaft Infektiologie und Infektimmunologie in Gynäkologie und Geburtshilfe (AGII);, Berufsverband der Frauenärzte (BVF);, Deutsche Gesellschaft für Pathologie (DGP);, Deutsche Gesellschaft für Urologie (DGU);, Deutsche Krebsgesellschaft (DKG) et al. S2 k Leitlinie zur Prävention, Diagnostik und Therapie der HPV-Infektion und präinvasiver Läsionen des weiblichen Genitale. 2010. Online: http://www.dggg.de/fileadmin/public_docs/Leitlinien/1-4-4-hpv-2010.pdf
    PubMedGoogle Scholar
  • 40 European Medicines Agency. Gardasil. 2012. Online: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp
    PubMedGoogle Scholar
  • 41 Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279-8284
    CrossrefPubMedGoogle Scholar
  • 42 Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750-757
    CrossrefPubMedGoogle Scholar
  • 43 Pomfret TC, Gagnon JM, Gilchrist AT. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 2011; 36: 1-9
    CrossrefPubMedGoogle Scholar
  • 44 Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011; 11: 13
    CrossrefPubMedGoogle Scholar
  • 45 Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Int Med 2012; 271: 193-203
    CrossrefPubMedGoogle Scholar
  • 46 Della Corte C, Carlucci A, Francalanci P, Alisi A, Nobili V. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011; 29: 4654-4656
    CrossrefPubMedGoogle Scholar
  • 47 Ojaimi S, Buttery JP, Korman TM. Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine 2009; 27: 4876-4878
    CrossrefPubMedGoogle Scholar
  • 48 Katoulis AC, Liakou A, Bozi E, Theodorakis M, Alevizou A, Zafeiraki A et al. Erythema multiforme following vaccination for human papillomavirus. Dermatology 2010; 220: 60-62
    CrossrefPubMedGoogle Scholar
  • 49 Perez-Carmona L, Aguayo-Leiva I, Gonzalez-Garcia C, Jaen-Olasolo P. The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration. Dermatology 2010; 221: 197-200
    CrossrefPubMedGoogle Scholar
  • 50 Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H et al. Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006–2009. Vaccine 2011; 29: 886-889
    CrossrefPubMedGoogle Scholar
  • 51 Alvarez-Soria MJ, Hernandez-Gonzalez A, Carrasco-Garcia de Leon S, del Real-Francia MA, Gallardo-Alcaniz MJ, Lopez-Gomez JL. Trastornos neurologicos desmielinizantes y vacunacion del papilomavirus humano [Demyelinating disease and vaccination of the human papillomavirus]. Revista de Neurologia 2011; 52: 472-476
    PubMedGoogle Scholar
  • 52 Bomprezzi R, Wildemann B. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2010; 74: 864-865
    PubMedGoogle Scholar
  • 53 Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry 2011; 82: 1296-1298
    CrossrefPubMedGoogle Scholar
  • 54 DiMario FJ, Hajjar M, Ciesielski T. A 16-year-old girl with bilateral visual loss and left hemiparesis following an immunization against human papilloma virus. J Child Neurol 2010; 25: 321-327
    CrossrefPubMedGoogle Scholar
  • 55 Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009; 72: 2132-2133
    CrossrefPubMedGoogle Scholar
  • 56 Mentzer D, Keller-Stanislawski B. Daten zur Pharmakovigilanz von Impfstoffen aus dem Jahr 2010. Bulletin zur Arzneimittelsicherheit 2012; 21-29
    PubMedGoogle Scholar
  • 57 Erlewyn-Lajeunesse M, Hunt LP, Heath PT, Finn A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child 2012; 97: 487-490
    CrossrefPubMedGoogle Scholar
  • 58 Brotherton JML, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S. Anaphylaxis following quadrivalent human papillomavirus vaccination. Can Med Ass J 2008; 179: 525-533
    CrossrefPubMedGoogle Scholar